Liver transplantation for malignancy

Oncologist

Volumn 10, Issue 4, 2005, Pages 269-281

  Hertl, Martin ^a,b   Cosimi, A Benedict ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Transplant Unit   (United States)

Author keywords

HCC; Hepatic malignancy; Liver transplantation; MELD

Indexed keywords

CYCLOSPORIN A; DOXORUBICIN;

ANGIOSARCOMA; BILE DUCT CARCINOMA; BONE MARROW TOXICITY; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARDIOTOXICITY; CHEMOEMBOLIZATION; CRYOTHERAPY; DIAGNOSTIC IMAGING; DRUG TOLERABILITY; GALLBLADDER CANCER; GRAFT REJECTION; HEMANGIOENDOTHELIOMA; HEPATOBLASTOMA; HUMAN; KIDNEY FAILURE; LIVER CANCER; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER METASTASIS; LIVER SURGERY; LIVER TRANSPLANTATION; LIVING DONOR; MATHEMATICAL MODEL; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; REVIEW; SCORING SYSTEM;

BILE DUCT NEOPLASMS; CARCINOMA, HEPATOCELLULAR; CHOLANGIOCARCINOMA; HEMANGIOENDOTHELIOMA, EPITHELIOID; HEPATOBLASTOMA; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MEDICAL ONCOLOGY; NEOPLASM METASTASIS; PATIENT SELECTION; SURVIVAL RATE; TREATMENT OUTCOME; WAITING LISTS;

EID: 17644392101     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.10-4-269     Document Type: Review

References (62)

1. National Cancer Institute. Age adjusted SEER incidence and U.S. death rates and 5-year relative survival rates. Available at http://seer.cancer.gov/ faststats. Accessed January 7, 2005.
2. Tsukuma H, Hiyama T, Tanaka S et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993;328:1797-1801.
3. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745-750.
4. Seeff LB. Natural history of hepatitis C. Am J Med 1999;107:10S-15S.
5. Maddrey WC, Lemon SM, Johnson LD. Introduction. Am J Med 1999;107(suppl 1):1S.
6. Wali MH, Heydtmann M, Harrison RF et al. Outcome of liver transplantation for patients infected by hepatitis C, including those infected by genotype 4. Liver Transpl 2003;9:796-804.
7. Davis GL. Hepatitis C virus genotypes and quasispecies. Am J Med 1999;107:21S-26S.
8. Zein NN, Rakela J, Krawitt EL et al. Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group. Ann Intern Med 1996;125:634-639.
9. Williams I. Epidemiology of hepatitis C in the United States. Am J Med 1999;107:2S-9S.
10. Ince N, Wands JR. The increasing incidence of hepatocellular carcinoma. N Engl J Med 1999;340:798-799.
11. Di Bisceglie AM. Malignant neoplasms of the liver. In: Schiff ER, Sorell MF, Maddrey WC, eds. Diseases of the Liver. Philadelphia: Lippincott-Raven, 1999:1281-1304.
12. Colombo M, de Franchis R, Del Ninno E et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 1991;325:675-680.
13. Sato Y, Nakata K, Kato Y et al. Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein. N Engl J Med 1993;328:1802-1806.
14. Koike Y, Shiratori Y, Sato S et al. Risk factors for recurring hepatocellular carcinoma differ according to infected hepatitis virus - an analysis of 236 consecutive patients with a single lesion. Hepatology 2000;32:1216-1223.
15. Arii S, Yamaoka Y, Futagawa S et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology 2000;32:1224-1229.
16. Yamamoto J, Okada S, Shimada K et al. Treatment strategy for small hepatocellular carcinoma: comparison of long-term results after percutaneous ethanol injection therapy and surgical resection. Hepatology 2001;34:707-713.
17. Groupe d'Etude et de Traitement du Carcinome Heptocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular cancer. N Engl J Med 1995;332:1256-1261.
18. Adachi E, Maehara S, Tsujita E et al. Clinicopathologic risk factors for recurrance after a curative hepatic resection for hepatocellular carcinoma. Surgery 2002;131(suppl 1):5148-5152.
19. Kanematsu T, Furui J, Yanaga K et al. A 16-year experience in performing hepatic resection in 303 patients with hepatocellular carcinoma: 1985-2000. Surgery 2002;131(suppl 1):S153-S158.
20. Suehiro T, Terashi T, Shiotani S et al. Liver transplantation for hepatocellular carcinoma. Surgery 2002;131(suppl 1):S190-S194.
21. Todo S, Furukawa H, Jin MB et al. Living donor liver transplantation in adults: outcome in Japan. Liver Transpl 2000;6(suppl 2):S66-S72.
22. Ringe B, Pichlmayr R, Wittekind C et al. Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients. World J Surg 1991;15:270-285.
23. Bismuth H, Chiche L, Adam R et al. Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann Surg 1993;218:145-151.
24. Bismuth H, Houssin D, Ornowski J et al. Liver resection in cirrhotic patients: a Western experience. World J Surg 1986;10:311-317.
25. Iwatsuki S, Starzl TE, Sheahan DG et al. Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg 1991;214:221-228; discussion 228-229.
26. Otto G, Heuschen U, Hofmann WJ et al. Survival and recurrence after liver transplantation versus liver resection for hepatocellular carcinoma: a retrospective analysis. Ann Surg 1998;227:424-432.
27. Fan ST, Lo CM, Lai EC et al. Perioperative nutritional support in patients undergoing hepatectomy for hepatocellular carcinoma. N Engl J Med 1994;331:1547-1552.
28. Freeman RB Jr. MELD/PELD: one year later. Transpl Proc 2003;35:2425-2427.
29. Cheng SJ, Freeman RB Jr, Wong JB. Predicting the probability of progression-free survival in patients with small hepatocellular carcinoma. Liver Transpl 2002;8:323-328.
30. US Transplant. Scientific Registry of Transplant Recipients. Available at http://152.160.76.234/csr_0105. Accessed January 7, 2005.
31. United Network for Organ Sharing. Available at http://www.unos.org/ PoliciesandBylaws/policies/pdfs/policy_8.pdf. Accessed January 7, 2005.
32. Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-699.
33. Fung J, Marsh W. The quandary over liver transplantation for hepatocellular carcinoma: the greater sin? Liver Transpl 2002;8:775-777.
34. Klintmalm GB. Liver transplantation for hepatocellular carcinoma: a registry report of the impact of tumor characteristics on outcome. Ann Surg 1998;228:479-490.
35. Molmenti EP, Klintmalm GB. Liver transplantation in association with hepatocellular carcinoma: an update of the International Tumor Registry. Liver Transpl 2002;8:736-748.
36. Haug CE, Jenkins RL, Rohrer RJ et al. Liver transplantation for primary hepatic cancer. Transpl Proc 1992;53:376-382.
37. Yao FY, Ferrell L, Bass NM et al. Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transpl 2002;8:765-774.
38. Yao FY, Bass NM, Nikolai B et al. Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list. Liver Transpl 2002;8:873-883.
39. Libbrecht L, Bielen D, Verslype C et al. Focal lesions in cirrhotic explant livers: pathological evaluation and accuracy of pretransplantation imaging examinations. Liver Transpl 2002;8:749-761.
40. Lim HK, Choi D, Lee WJ et al. Hepatocellular carcinoma treated with percutaneous radio-frequency ablation: evaluation with follow-up multiphase helical CT. Radiology 2001;221:447-454.
41. Krinsky GA, Lee VS, Theise ND et al. Hepatocellular carcinoma and dysplastic nodules in patients with cirrhosis: prospective diagnosis with MR imaging and explantation correlation. Radiology 2001;219:445-454.
42. Cheng SJ, Pratt DS, Freeman RB Jr et al. Living-donor versus cadaveric liver transplantation for non-resectable small hepatocellular carcinoma and compensated cirrhosis: a decision analysis. Transplantation 2001;72:861-868.
43. Gondolesi G, Munoz L, Matsumoto C et al. Hepatocellular carcinoma: a prime indication for living donor liver transplantation. J Gastrointest Surg 2002;6:102-107.
44. The Organ Procurement and Transplantation Network. Policy Notice, OPTN/UNOS Board of Directors, April 7, 2003. Available at http://www.optn.org/ latestData/rptStrat.asp. Accessed June 19, 2004.
45. Vivarelli M, Bellusci R, Cucchetti A et al. Low recurrence rate of hepatocellular carcinoma after liver transplantation: better patient selection or lower immunosupression? Transplantation 2002;74:1746-1751.
46. De la Revilla NJ, Moreno JM, Rubio E et al. Usefulness of chemotherapy as prophylaxis of tumor recurrence after liver transplantation in advanced hepatocellular carcinomas. Transpl Proc 2003;35:1830-1831.
47. El-Serag HB, Davila JA. Is fibrolamellar carcinoma different from hepatocellular carcinoma? A US population-based study. Hepatology 2004;39:798-803.
48. Ringe B, Wittekind C, Weimann A et al. Results of hepatic resection and transplantation for fibrolamellar carcinoma. Surg Gynecol Obstet 1992;175:299-305.
49. Pinna AD, Iwatsuki S, Lee RG et al. Treatment of fibrolamellar hepatoma with subtotal hepatectomy or transplantation. Hepatology 1997;26:877-883.
50. O'Grady JG. Treatment options for other hepatic malignancies. Liver Transpl 2000;6(suppl 2):S23-S29.
51. Meyer CG, Penn I, James L. Liver transplantation for cholangiocarcinoma: results in 207 patients. Transplantation 2000;69:1633-1637.
52. Goss JA, Shackleton CR, Farmer DG et al. Orthotopic liver transplantation for primary sclerosing cholangitis: a 12-year single center experience. Ann Surg 1997;225:472-481; discussion 481-483.
53. De Vreede I, Steers JL, Burch PA et al. Prolonged disease-free survival after orthotopic liver transplantation plus adjuvant chemoirradiation for cholangiocarcinoma. Liver Transpl 2000;6:309-316.
54. Gores GJ. Early detection and treatment of cholangiocarcinoma. Liver Transpl 2000;6(suppl 2):S30-S34.
55. Madariaga JR, Marino IR, Karavias DD et al. Long-term results after liver transplantation for primary hepatic epitheloid hemangioendothelioma. Ann Surg Oncol 1995;2:483-487.
56. Penn I. Hepatic transplantation for primary and metastatic cancers of the liver. Surgery 1991;110:726-734; discussion 734-735.
57. Otte JB, Pritchard J, Aronson DC et al. Liver transplantation for hepatoblastoma: results from the International Society of Pediatric Oncology (SIOP) study SIOPEL-1 and review of the world experience. Pediatr Blood Cancer 2004;42:74-83.
58. Srinivasan P, McCall J, Pritchard J et al. Orthotopic liver transplantation for unresectable hepatoblastoma. Transplantation 2002;74:652-655.
59. Pimpalwar AP, Sharif K, Ramani P et al. Strategy for hepatoblastoma management: transplant versus nontransplant surgery. J Pediatr Surg 2002;37:240-245.
60. Le Treut YP, Delpero JR, Dousset B et al. Results of liver transplantation in the treatment of metastatic neuroendocrine tumors: a 31-case French multicentric report. Ann Surg 1997;225:355-364.
61. Coppa J, Pulvirenti A, Schiavo M et al. Resection versus transplantation for liver metastases from neuroendocrine tumors. Transplant Proc 2001;33:1537-1539.
62. Lang H, Oldhafer KJ, Weimann A et al. Liver transplantation for metastatic neuroendocrine tumors. Ann Surg 1997;225:347-354.